Viet Huy successfully transfers a MULTI-GENE targeted therapy testing solution to Binh Dan Hospital

Effective, Comprehensive Technology Transfer in Clinical Practice

With dedicated support from Viet Huy's team of specialists and the professional cooperation of the hospital's doctors and laboratory technicians, the transfer process went smoothly and effectively. The transferred MULTI-GENE test kit covers genes related to targeted therapy, such as KRAS, NRAS, BRAF, PIK3CA and AKT1, enabling comprehensive and accurate detection of mutations in colorectal cancer.

In just two days, the medical team mastered the use of this technology and kit, improving accuracy in making fast treatment decisions tailored to each patient.

Figure 1: A Viet Huy specialist carefully guiding how to run the MULTI-GENE test kit.

Figure 2: The testing process at Binh Dan Hospital.

Figure 3: Souvenir photo at the Department of Andrology - Binh Dan Hospital

A Step Forward in Targeted Therapy

Using the real-time PCR technique combined with the MULTI-GENE test kit, doctors can quickly detect gene mutations relevant to targeted therapy for colorectal cancer (CRC), including:

Gene	Frequency in CRC (%)	Main mutations identified	Impact on therapy and prognosis
KRAS	36-40%	Codon 12, 13	Resistance to anti-EGFR therapy (e.g., cetuximab, panitumumab). Screening recommended by ASCO.
NRAS	1-6%	Exon 2 (codon 12/13), Exon 3 (codon 61), Exon 4 (codon 146)	Resistance to anti-EGFR therapy in the absence of KRAS/BRAF mutations.
BRAF	8-10%	V600E mutation	Resistance to anti-EGFR therapy, poor prognosis, shorter disease-free and overall survival.
PIK3CA	10-30%	Exon 9 (helical domain), Exon 20 (kinase domain)	Associated with resistance to anti-EGFR therapy; a potential target for PI3K inhibitors.
AKT1	1-6%	E17K mutation	Reduced sensitivity to AKT inhibitors; usually lacks other driver mutations (EGFR, KRAS, ALK).

As a result, targeted therapy regimens are personalized for each patient, improving treatment effectiveness and quality of life.

The technology transfer at Binh Dan Hospital marks an important milestone, opening up opportunities for many colorectal cancer patients to access modern, optimal diagnostic and treatment solutions.

Targeted Therapy Testing - Viet Huy's Pioneering Role

Viet Huy continues to affirm its pioneering role in bringing advanced IVD molecular diagnostic solutions to leading hospitals in Vietnam. This transfer of the MULTI-GENE test kit improves treatment effectiveness and contributes to positive changes in healthcare.

The collaboration between Binh Dan Hospital and Viet Huy has marked an important milestone in targeted therapy for colorectal cancer in Vietnam. By applying advanced molecular diagnostics solutions, doctors have succeeded in optimizing personalized treatment regimens and achieving outstanding treatment outcomes. This breakthrough not only opens up new chances of survival but also significantly improves quality of life, bringing hope to thousands of patients and their families.

Viet Huy is proud to accompany Binh Dan Hospital on its journey of innovation and raising healthcare standards in Vietnam. We sincerely thank Binh Dan Hospital for its trust and are committed to continuing to deliver modern technology solutions that help improve the quality of community healthcare.

Viet Huy - Leading Innovation in Molecular Diagnostics

For nearly 20 years, Viet Huy has established a leading position in the molecular diagnostics industry in Vietnam. More than just a supplier of testing reagents, we are a trusted partner providing comprehensive solutions, from in-depth training to modern technical support, that meet the most stringent requirements of the healthcare sector.

Every step Viet Huy takes is aimed at the highest goal: optimizing efficiency, improving quality and enhancing the investment value for our healthcare partners.

Viet Huy - Leading in Technology, Joining Hands for Community Health